Michael Bitzer

15PUBLICATIONS
99CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapyPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Apr 17, 2026
Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial.

|Feb 27, 2026
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience

|Apr 02, 2025
Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps.

Beryl Primrose Gladstone, Janina Beha, Arisa Hakariya

|Mar 07, 2025
Retrieval Augmented Therapy Suggestion for Molecular Tumor Boards: Algorithmic Development and Validation Study.

Eliza Berman, Holly Sundberg Malek, Michael Bitzer

|Feb 12, 2024
The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.

Stephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko

|Oct 24, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.

Maria Pouyiourou, Bianca N Kraft, Timothy Wohlfromm

Pageof 3

Frequent Collaborators

2 joint publications

Albrecht Stenzinger

2 joint publications

Peter Horak

2 joint publications

Klaus Schulze-Osthoff

2 joint publications

Siri Göpel